What's better than a good thing? More of a good thing. Income investors can find plenty of "good things" in the market these ...

Pfizer Inc. closed 18.10% below its 52-week high of $31.54, which the company reached on July 30th.

In a report released today, Elmar Kraus from DZ BANK AG maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares opened ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Today, Benzinga's options scanner spotted 33 options trades for Pfizer. This is not a typical pattern. The sentiment among these major traders is split, with 66% bullish and 33% bearish. Among all the ...

Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.9% year on year to $17.76 billion. On the other hand, the company ...

These sensational income stocks -- sporting an average yield of 6.15% -- can fatten investors' pocketbooks for a long time to ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Cramer noted that the Dow plunged by 337 points, the S&P 500 fell 0.5%, and the Nasdaq declined by 0.28%. Adding fuel to the ...